Corbus Pharmaceuticals said its Phase 1b obesity drug trial met a key early mark, with the 60 mg dose of CRB-913 delivering 5% mean weight loss after 12 weeks. All three doses showed statistically significant results, supporting further development.
published
Corbus Pharmaceuticals said its Phase 1b obesity drug trial met a key early mark, with the 60 mg dose of CRB-913 delivering 5% mean weight loss after 12 weeks. All three doses showed statistically significant results, supporting further development.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.